Johnson & Johnson (JNJ)vsMetaVia Inc. (MTVA)
JNJ
Johnson & Johnson
$240.45
+0.85%
HEALTHCARE · Cap: $579.46B
MTVA
MetaVia Inc.
$1.22
-7.58%
HEALTHCARE · Cap: $4.31M
Smart Verdict
WallStSmart Research — data-driven comparison
JNJ leads profitability with a 28.5% profit margin vs 0.0%. JNJ earns a higher WallStSmart Score of 71/100 (B).
JNJ
Strong Buy71
out of 100
Grade: B
MTVA
Avoid26
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+53.5%
Fair Value
$516.67
Current Price
$240.45
$276.22 discount
Intrinsic value data unavailable for MTVA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Keeps 29 of every $100 in revenue as profit
Strong operational efficiency at 24.0%
Earnings expanding 48.6% YoY
Generating 5.5B in free cash flow
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 28.5% and operating margin at 24.0%.
Bull Case : MTVA
The strongest argument for MTVA centers on Price/Book.
Bear Case : JNJ
The primary concerns for JNJ are PEG Ratio.
Bear Case : MTVA
The primary concerns for MTVA are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
JNJ profiles as a mature stock while MTVA is a value play — different risk/reward profiles.
JNJ carries more volatility with a beta of 0.33 — expect wider price swings.
JNJ is growing revenue faster at 9.1% — sustainability is the question.
JNJ generates stronger free cash flow (5.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (71/100 vs 26/100), backed by strong 28.5% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →MetaVia Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
MetaVia Inc. is an innovative technology firm at the forefront of delivering cutting-edge digital solutions aimed at enhancing connectivity and productivity across various industries. Leveraging advanced artificial intelligence and cloud computing, the company offers scalable platforms tailored to meet the distinct needs of its diverse clientele. MetaVia's strong commitment to sustainability and social responsibility not only aligns with evolving market demands but also positions it for substantial growth, ultimately enhancing shareholder value. With a strategic approach centered on adaptability and collaboration, MetaVia is poised to thrive and lead in the rapidly changing technology landscape.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?